Liberty One Investment Management LLC Has $29.54 Million Stake in Eli Lilly and Company (NYSE:LLY)

Liberty One Investment Management LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,769 shares of the company's stock after selling 1,670 shares during the quarter. Eli Lilly and Company accounts for 3.0% of Liberty One Investment Management LLC's holdings, making the stock its 11th biggest position. Liberty One Investment Management LLC's holdings in Eli Lilly and Company were worth $29,542,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Stratos Investment Management LLC boosted its position in Eli Lilly and Company by 18.1% during the 1st quarter. Stratos Investment Management LLC now owns 8,284 shares of the company's stock worth $6,842,000 after acquiring an additional 1,270 shares during the last quarter. Blackhawk Capital Partners LLC. boosted its position in Eli Lilly and Company by 41.7% during the 1st quarter. Blackhawk Capital Partners LLC. now owns 8,516 shares of the company's stock worth $7,033,000 after acquiring an additional 2,504 shares during the last quarter. Black Diamond Financial LLC boosted its position in Eli Lilly and Company by 35.6% during the 1st quarter. Black Diamond Financial LLC now owns 2,996 shares of the company's stock worth $2,475,000 after acquiring an additional 786 shares during the last quarter. May Hill Capital LLC boosted its position in Eli Lilly and Company by 1.3% during the 1st quarter. May Hill Capital LLC now owns 1,582 shares of the company's stock worth $1,307,000 after acquiring an additional 21 shares during the last quarter. Finally, Brown Advisory Inc. boosted its position in Eli Lilly and Company by 1.1% during the 1st quarter. Brown Advisory Inc. now owns 107,981 shares of the company's stock worth $89,182,000 after acquiring an additional 1,125 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

LLY stock traded up $2.69 during trading hours on Friday, hitting $793.34. 2,821,127 shares of the stock were exchanged, compared to its average volume of 3,667,032. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $751.88 billion, a P/E ratio of 64.55, a P/E/G ratio of 1.15 and a beta of 0.40. The company has a 50-day simple moving average of $767.03 and a two-hundred day simple moving average of $800.01. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.58 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is 48.82%.

Analysts Set New Price Targets

Several research firms have recently commented on LLY. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Cantor Fitzgerald began coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. UBS Group cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.